PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS
Despite the unprecedented success in using immune checkpoint inhibitors in the treatment of lung cancer, melanoma, hypermutable tumors of various localization, etc., a significant proportion of patients receiving these drugs do not respond to treatment. Predictive markers routinely used in the selec...
Main Authors: | G. A. Janus, A. G. Ievleva, E. N. Suspitsyn, V. I. Tyurin, I. V. Bizin, O. A. Gorustovich, V. I. Ni, M. M. Kholmatov, T. A. Laidus, S. A. Chuynyshena, S. N. Aleksakhina, E. N. Imyanitov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Tomsk National Research Medical Center of the Russian Academy of Sciences
2020-09-01
|
Series: | Sibirskij Onkologičeskij Žurnal |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/1538 |
Similar Items
Similar Items
-
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01) -
Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017-05-01) -
Key questions about the checkpoint blockade-are microRNAs an answer?
by: Mihnea Dragomir, et al.
Published: (2018-06-01) -
Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01) -
Immunotherapy in genitourinary malignancies
by: Kathan Mehta, et al.
Published: (2017-04-01)